[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628259":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":19,"locations":25,"responsibleParty":41,"collaborators":18,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":18,"eligibilityCriteria":50,"healthyVolunteers":47,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":18,"studyType":57,"phases":58,"briefSummary":49,"conditions":60,"keywords":18,"overallStatus":63,"whyStopped":18,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Fudan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Group","EXPERIMENTAL","Multimodal Tumor Thermal Ablation",[13],"Device: Multimodal Tumor Thermal Ablation",[15],{"type":16,"name":11,"description":11,"armGroupLabels":17,"otherNames":18},"DEVICE",[9],null,[20],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"wentao li","CONTACT","+86 13774225887","liwentao98@126.com",[26],{"facility":27,"status":18,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Fudan University Shanghai Cancer Center","Shanghai","Shanghai Municipality","200000","China","CN",{"type":34,"coordinates":35},"Point",[36,37],121.45806,31.22222,{"lat":37,"lon":36},[40],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Wen-Tao Li","Director of Interventional Therapy Department,Fudan University","100628259","clinical-study-on-the-safety-efficacy-and-exploration-of-immune-mechanisms-of-a-combined-multimodal-tumor-therapy-system-for-hepatic-malignancies-100628259",false,"NCT07459309","Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic Malignancies","Inclusion Criteria:\n\n1. Age 18-80 years, regardless of gender;\n2. Histopathologically confirmed or clinically diagnosed hepatic malignancies, including primary liver cancer and metastatic liver cancer;\n3. Presence of an image-evaluable target lesion for ablation, with the maximum diameter of the target lesion being 3-5 cm;\n4. Patient is intolerant to or refuses surgical resection;\n5. ECOG performance status score ≤ 2, with an expected survival period of greater than 3 months.\n\nExclusion Criteria:\n\n1. Liver function classified as Child-Pugh C, unimprovable with hepatoprotective therapy;\n2. Massive or diffuse hepatocellular carcinoma;\n3. Presence of vascular tumor thrombus or invasion of adjacent organs;\n4. History of esophageal (gastric fundus) variceal rupture and bleeding within 1 month prior to treatment;\n5. Uncorrectable coagulation dysfunction and severe hematological abnormalities, with a high risk of severe bleeding;\n6. Refractory massive ascites, cachexia;\n7. Active infection, especially inflammatory conditions of the biliary system;\n8. Severe functional failure of major organs such as liver, kidney, heart, lung, and brain;\n9. Impaired consciousness, or inability to cooperate with treatment;\n10. Previous systemic treatments (e.g., chemotherapy) with an interval of less than 2 weeks and not having recovered from prior treatment: CTCAE 6.0 grade \\>1 (except for alopecia);\n11. Any other factors deemed by the investigator to make the subject unsuitable for participation or to affect the subject's involvement in the study.","ALL","18 Years","80 Years",{"count":55,"type":56},20,"ESTIMATED","INTERVENTIONAL",[59],"NA",[61,62],"Liver Cancer (Primary and Metastatic)","Liver Ablation","NOT_YET_RECRUITING","2026-03-04",{"date":66,"type":67},"2026-03-09","ACTUAL",{"date":69,"type":56},"2026-03-16",{"date":71,"type":56},"2027-12-31",{"name":5,"class":6},1]